Innovest Global Announces Patent is Approved for StemVax Therapeutics

Las Vegas, Nevada, UNITED STATES

CLEVELAND, July 25, 2018 (GLOBE NEWSWIRE) -- Innovest Global Inc. (OTC Pink Current:IVST) (the “Company” or “Innovest”), reports that the patent application for the technology being developed by StemVax Therapeutics was approved. The patent is granted under the category of “Cancer Antigens”, and related to the “treatment of cancer using vaccination therapy”.

“Patent approval is the trigger for us to engage major health organizations, to continue the progress toward the ‘StemVax Glioblast’ brain tumor vaccine going to market and improving peoples lives. After decades of research, it took nine years in the patent process, and is a transformational achievement,” said Dr. Dwain Morris-Irvin, President of Innovest’s Biotech Division. The patent application was filed in 2008 by a hospital research organization, and was co-authored by Dr. Morris-Irvin, who is also the StemVax Chief Science Officer. It is patent #US9764014B2.

“This is very significant. I am thrilled for the StemVax team, and in awe of how well positioned this technology is, how many people it can help, and how enthusiastic Dr. Morris-Irvin is about next steps,” said Dan Martin, CEO of Innovest Global. “Everyone who knows Dwain, knows his passion for this work. He and his colleagues sacrifice immensely and work very hard. The world is a better place thanks to professionals like these, and others, who are committed to the research process with no assurances of when, or even if, a breakthrough may occur. They deserve the utmost respect and admiration for their efforts.”

StemVax is organizing its market approach, and finalizing key arrangements. Sufficiently demonstrating valid intellectual property to Innovest was one of Innovest’s requirements to ultimately closing the StemVax transaction last week, which was pending since a Letter of Intent was signed and announced on March 19, 2018, contingent upon certain StemVax achievements. Innovest’s acquisition of a stake in StemVax was announced July 18, 2018, and marked the launch of the Innovest Biotechnology & Health Services Division. Look for much more to news to come soon about this exciting effort.

More about StemVax Therapeutics:

StemVax Therapeutics is a Translational Biotechnology Company that develops novel therapies for brain tumor patients. We focus our efforts on developing immunotherapeutic approaches to treating patients with Glioblastoma Multiforme (GBM), a devastating brain cancer. We also focus our research efforts on novel drug development to target Cancer Stem cells and other multi-resistant cancer cells. We seek to make a difference in patient’s lives. Bringing new beginnings to the market by developing novel therapeutics.

About Innovest Global, Inc.
Innovest Global, Inc. (OTC Markets:IVST) is in the Conglomerates industry, a diversified holding company with operations in commercial and industrial products and services, energy, biotechnology, and health services. Innovest Global utilizes novel technology and marketing to efficiently acquire customers. Our primary growth strategy is to acquire existing companies in a select few industries, and attract new customers in cost effective ways. Currently, we have a Commercial & Industrial Division, and a Biotechnology & Health Services Division.

For more information, please visit:, and follow us on Twitter @innovestglobal.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company's control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company's filings with the OTC Markets. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Contact Information
Corporate Office:
(216) 815-1122
Twitter @innovestglobal 

Investor Relations:
Hayden IR
(917) 658-7878